Cue Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$6.64next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly16.4MTarget: Sufficient capital to fund expected clinical milestones for CUE-221 and CUE-401
Collaboration Revenue Quarterly5.7MTarget: Expansion of strategic partnerships and milestone achievements
Watch Items
- CUE-221 (formerly Ascendant-221) Phase 2 CSU Clinical Results in ChinaTrigger: Clinical results expected in 2H 2026Action: Review data to decide on initiating global Phase 2b trial in food allergy
- CUE-401 IND SubmissionTrigger: IND submission expected in 2H 2026Action: Prepare for Phase 1 first-in-human study initiation by year-end 2026
- Going Concern and Capital RunwayTrigger: Inability to continue operations beyond 12 months without additional financingAction: Leverage the $30 million private placement and $7.5 million Boehringer Ingelheim milestone to extend runway
Research as of 20 Jun 2026